Additionally, with the successful prospective trials of anti-programmed death 1 (anti-PD-1) and anti-programmed death ligand 1 (anti-PD-L1) for advanced HCC, the treatment for HCC has stepped into the novel era of immunotherapy (34). This evidence concerns the gene CD274 and hepatocellular carcinoma.